[Effects of the RALE study. Hyperkalemia following spironolactone treatment].
Erdmann
E
E
III. Medizinische Klinik der Universität Köln. erland-erdmann@uni-koeln.de
D000319:Adrenergic beta-Antagonists / Q000009:adverse effects / Q000627:therapeutic use; D016907:Adverse Drug Reaction Reporting Systems; D000368:Aged; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D011307:Drug Prescriptions / Q000706:statistics & numerical data; D004359:Drug Therapy, Combination; D004363:Drug Utilization / Q000639:trends*; D005260:Female; D006333:Heart Failure / Q000188:drug therapy*; D017052:Hospital Mortality / Q000639:trends; D006760:Hospitalization / Q000639:trends; D006801:Humans; D006947:Hyperkalemia / Q000139:chemically induced* / Q000150:complications / Q000401:mortality; D008297:Male; D000451:Mineralocorticoid Receptor Antagonists / Q000009:adverse effects* / Q000627:therapeutic use; D010818:Practice Patterns, Physicians' / Q000639:trends; D016032:Randomized Controlled Trials as Topic; D013148:Spironolactone / Q000009:adverse effects* / Q000627:therapeutic use
D000319:Adrenergic beta-Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D000451:Mineralocorticoid Receptor Antagonists; D013148:Spironolactone
J Am Coll Cardiol. 2003 Aug 20;42(4):705-8
12932605
N Engl J Med. 2003 Apr 3;348(14):1309-21
12668699
BMJ. 2003 Jul 19;327(7407):147-9
12869459
N Engl J Med. 2004 Aug 5;351(6):543-51
15295047
N Engl J Med. 2001 Dec 6;345(23):1689-97
11759649
N Engl J Med. 1999 Sep 2;341(10):709-17
10471456